Immunovant
IMVT
209 hedge funds and large institutions have $2.27B invested in Immunovant in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 82 increasing their positions, 79 reducing their positions, and 46 closing their positions.
83% more call options, than puts
Call options by funds: $42.8M | Put options by funds: $23.4M
4% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 79
0.79% more ownership
Funds ownership: 47.65% → 48.45% (+0.79%)
8% less funds holding
Funds holding: 228 → 209 (-19)
22% less capital invested
Capital invested by funds: $2.9B → $2.27B (-$631M)
39% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 46
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$66M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$29.2M |
| 3 |
AC
Armistice Capital
New York
|
+$26.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.7M |
| 5 |
PA
Perceptive Advisors
New York
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$49.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$44.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$21.3M |
| 5 |
Jane Street
New York
|
-$19.9M |
IMVT Hedge Fund Activity: Q1 2024 in Review
209 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2024, worth a combined $2.27B — down 22% from $2.9B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of IMVT and 28 opened new positions — a net loss of 18 holders — while 79 trimmed existing stakes and 82 added.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $66M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $49.1M sold.
- 209 institutional investors held Immunovant (IMVT) as of Q1 2024, down from 228 in Q4 2023.
- Funds reported $2.27B of Immunovant stock for Q1 2024, down 22% quarter-over-quarter.
- 28 funds opened new Immunovant positions in Q1 2024 and 46 closed out, a net change of -18 holders.
- The largest Immunovant buyer in Q1 2024 was Viking Global Investors, an estimated $66M added.
- The largest Immunovant seller in Q1 2024 was Cormorant Asset Management, an estimated $49.1M sold.
Based on aggregated 13F filings for Q1 2024.